BioSpace News Archive

United Therapeutics Corporation (Nasdaq: UTHR) and DEKA Research & Development Corp. today announced receipt of an additional 510(k) clearance by the U.S. Food and Drug Administration (FDA) related to the Unity Subcutaneous Delivery System for Remodulin® (treprostinil) Injection

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that John A. Hohneker, M.D., president and chief executive officer of Anokion, will present a company overview at the Cowen 40th Annual Healthcare Conference

Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax’’ or the ''Company’’), an outcome-driven connected healthcare company, today announced it has reached a settlement and release of all potential liabilities and litigation with the previous owner of RoxSan Pharmacy, Inc., (the “RoxSan Owner”) stemming from its ownership of RoxSan.

Progressive Care Inc., a personalized healthcare services and technology company, announced that CEO, S. Parikh Mars, will be the keynote speaker at Cold Chain Global Forum West Coast in San Diego, CA on February 26-27, 2020.

Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the results of its Post Action meeting with the U.S. Food and Drug Administration (“FDA’) regarding its New Drug Application (“NDA”) for TLANDO™,

Avanos Medical, Inc. (NYSE: AVNS) today announced that it would present at the following two investor conferences in March:

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ solutions as prescription medical treatments, today announced that Ross Muken, Chief Financial Officer, will give a corporate presentation and will participate in a digital therapeutics panel discussion at the Cowen and Company 40th Annual Healthcare Conference.

ASLAN Pharmaceuticals Limited announced its presentation at the 9th Annual SVB Leerink Global Healthcare Conference.

Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced that it has entered into a research collaboration with GSK for its protein-based coronavirus vaccine candidate.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that aggregated results from 309 children treated with Ryoncil™ (remestemcel-L) were presented at the American Society for Transplantation Cellular Therapy and the Center for International Blood & Bone Marrow Transplant Research (TCT) meeting in Orlando, Florida on February 22.